AL8326 / Advenchen - LARVOL DELTA

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC (clinicaltrials.gov) - P2 | N=36 | Active, not recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase IIII Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=243 | Recruiting | Sponsor: Advenchen Laboratories Nanjing Ltd.

Metastases • New P3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment. (ASCO 2023) - P1/2, P2 | "AL8326 has demonstrated acceptable tolerability and positive efficacy on small cell lung cancer treatment. A US Phase 2 (NCT05363280) study is ongoing and a phase 3 study is in preparation. Clinical trial information: NCT04890795."

Clinical • Monotherapy • P1/2 data • Anorexia • Cardiovascular • Dyslipidemia • Hematological Disorders • Hypertension • Hypertriglyceridemia • Lung Cancer • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Renal Disease • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC. | Initiation date: Jul 2022 ➔ Nov 2022

Trial initiation date • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Advenchen Laboratories Nanjing Ltd.

New P1 trial

AL8326 in SCLC Treatment (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC.

New P2 trial • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase I Study of AL8326 in Advanced Solid Tumor (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Advenchen Laboratories Nanjing Ltd.

New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer (clinicaltrials.gov) - P1/2; N=237; Recruiting; Sponsor: Advenchen Laboratories Nanjing Ltd.

Clinical • New P1/2 trial • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor